Samsung Biologics Plans to Open a 4th Manufacturing Super Plant

Samsung Biologics announced plans to break ground on a fourth plant by the end of this year. Plant 4 is expected to commence manufacturing activities by the second half of 2022 and is part of a long-term strategy to increase its operational capacity and scale overall capabilities to fit the needs of clients everywhere. We’ll look at what this plant means, what it can do, and how it fits into the larger expansion plans of the company.

A Focus on Growth

Spurred on by the COVID-19 pandemic, Samsung Biologics sees this expansion as a way for the CDMO to meet the increase in demand for pharmaceuticals all over the world. 

It’s also why the company is already in negotiations with the Incheon Free Economic Zone (IFEZ) to buy additional land for a second bio complex. These two investments (Plant 4 and the bio complex) are expected to equal around $2 billion USD—more than the total amount invested in the company’s previous three plants combined.

Samsung Biologics believes that this approach is the best way to offer its clients more comprehensive services. Plant 4 will add a 256KL capacity to the site, bringing its holdings up to 620KL upon completion. By offering multi-scale manufacturing, the company can bring more value to its clients and further attract trusted brands in the biopharmaceutical industry.

The Expansion Plans

The construction of the plant will begin on an existing site comprising of nearly 238,000 square meters in total floor area. (That’s about the total combined size of its three existing plants.) Its primary purpose is to hone operational efficiency, introducing a real-time schedule with the help of automation and the latest in biomanufacturing technology.

The future plant will also integrate data regarding its utility supply from its other plants to further optimize its production. Finally, Samsung Biologics is also investing in offsetting its facilities’ environmental impact. It will dispose of high-concentration wastewater responsibly and control its nitric acid emissions, all while adding more than 1,800 jobs to the community.

As for the second bio complex, the project is expected to be built near the current complex and encompass roughly 330,000 square meters. Once the terms of the negotiation are finalized, the company will use the space for a variety of initiatives. For instance, an Open Innovation Center where biotech companies can come together to share ideas and grow. Samsung Biologics will also build an R&D facility and set aside space for future plants within the second complex.

Becoming The Global Standard Through Innovation

As Samsung Biologics looks to become the leading global standard in the industry, the “Super Plant” (as it’s been nicknamed) will raise the bar even further in ensuring production efficiency and providing top-notch services in new mid- and small-scale facilities.

After construction, the plant will be the single largest biologics generator and have the capabilities to take on cell line development, sample manufacturing, active ingredient manufacturing, drug substance manufacturing, and fill-and finish product manufacturing. It’s expected to dramatically reduce the amount of time needed to safely make a medication or therapy commercially available.

In this continuously evolving climate, innovation is key. While clients of Samsung Biologics might initially be drawn to the company for a specific reason—meeting regulatory compliance measures, needing a larger production facility to keep up with demand, etc. —what they find is that Samsung Biologics can help them with so much more. From the idea to the packaging, Samsung Biologics has the resources to assist from start to finish. Plant 4 will use the best in design from the first three plants to offer additional manufacturing services for the benefit of the entire industry.

The Samsung Biologics Promise

The biologics drug market is expected to grow by 8% every year, and contract development and manufacturing is expected to grow by 16%. The combination of new threats on the horizon, such as the coronavirus, and rapidly aging society will only continue to fuel the demand.

The award-winning Samsung Biologics is a fully integrated pharmaceutical contract development and manufacturing organization (CDMO) with the resources and expertise required to fit the ever-changing needs of clients and patients.

About RJ Frometa

Head Honcho, Editor in Chief and writer here on VENTS. I don't like walking on the beach, but I love playing the guitar and geeking out about music. I am also a movie maniac and 6 hours sleeper.

Check Also

4 Things to Consider Before Returning to Work After COVID-19

Over the last few months, you have likely been working remotely. When the lockdown began, …

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.